一分钟看懂
这是一项关于髓系恶性肿瘤的I 期研究，登记的药物或干预包括BG-75202；Hypomethylation Agent (HMA)，当前状态为招募中。登记地点显示中国兰州、广州、石家庄、郑州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BG-75202；Hypomethylation Agent (HMA) · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Hospital of Lanzhou University · 兰州
- Zhujiang Hospital of Southern Medical University · 广州
- The Second Hospital of Hebei Medical University · 石家庄
- The First Affiliated Hospital of Zhengzhou Universitysouth Branch · 郑州
- Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology · 武汉
- The First Affiliated Hospital of Soochow University · 苏州
- The First Affiliated Hospital of Nanchang University Branch Donghu · 南昌
- The First Affiliated Hospital of Nanchang University Branch Xianghu · 南昌
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciencestuanbo Branch · 天津
公开的入选条件
- * Patients must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), inclusive, at the time of signing the Informed consent form (ICF).
- * Patients must have a confirmed diagnosis of myeloid malignancies based on 2016 World Health Organization criteria, and meet the following categories:
- Relapsed/refractory; myeloid malignancies after ≥1 prior systemic therapy, per ELN; 2022 criteria; patients with actionable genetic alteration must have previously received targeted therapies unless contraindicated, unavailable/inaccessible, or declined by pat
- * Patients must have a stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07619287；登记信息更新于 2026-09-14。